PMGC Holdings (ELAB) Enterprise Value (2022 - 2026)
PMGC Holdings (ELAB) posted Enterprise Value of -$15.1 million for Q1 2026, down 152.54% sequentially from -$6.0 million in Q4 2025, and down 154.78% YoY from $27.5 million in Q1 2025.
PMGC Holdings (ELAB) Enterprise Value (2022 - 2026) Analysis & Trends
PMGC Holdings has reported Enterprise Value for 5 years, with the latest figure at -$15.1 million in Q1 2026.
- Quarterly Enterprise Value fell 154.78% year-over-year to -$15.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$15.1 million (down 154.78% YoY) and the FY2025 annual result came in at -$6.0 million, down 49.9% from the prior year.
- Enterprise Value fell to -$15.1 million in Q1 2026 per ELAB's latest filing, from -$6.0 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$100034.0 in Q2 2024 and troughed at -$1.6 billion in Q3 2022.
- A 5-year average of -$108.9 million and a median of -$4.0 million in 2024 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2023 and 2025: Enterprise Value soared 99.97% in 2023, then plunged 6205.32% in 2025.
- Over 5 years, Enterprise Value stood at -$1.2 million in 2022, then slumped by 188.06% to -$3.3 million in 2023, then declined by 19.8% to -$4.0 million in 2024, then plunged by 49.9% to -$6.0 million in 2025, then plunged by 152.54% to -$15.1 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$15.1 million, -$6.0 million, and -$8.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.29 Bn | 132.43 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.58 Bn | 78.58 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.08 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 61.87 Bn | 56.73 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.18 Bn | 37.08 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.51 Bn | 28.20 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.90 Bn | 10.51 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 2.12 Bn |
| 10 | PMGC Holdings | 30.43 Mn | 11.64 Mn | 385,691.00 | -18.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.09 Mn |
| Dec 31, 2025 | -5.97 Mn |
| Sep 30, 2025 | -8.50 Mn |
| Jun 30, 2025 | -6.31 Mn |
| Mar 31, 2025 | -5.92 Mn |
| Dec 31, 2024 | -3.99 Mn |
| Sep 30, 2024 | -6.43 Mn |
| Jun 30, 2024 | -100,034.00 |
| Mar 31, 2024 | -943,797.00 |
| Dec 31, 2023 | -3.33 Mn |
| Sep 30, 2023 | -476,855.00 |
| Jun 30, 2023 | -601,265.00 |
| Mar 31, 2023 | -1.05 Mn |
| Dec 31, 2022 | -1.15 Mn |
| Sep 30, 2022 | -1.57 Bn |